Background: Varenicline has been reported to reduce drinking in smokers and to selectively decrease responding for ethanol (EtOH) versus alternatives in preclinical studies. Such selectivity may reflect potential therapeutic effects and the involvement of nicotinic receptors in EtOH reinforcement. However, these studies have been conducted with EtOH and an alternative available in isolation or in separate groups, and selectivity can depend on the context in which reinforcement occurs. Whether varenicline selectivity is maintained when EtOH and an alternative are concurrently available has not been reported. To examine the effects of varenicline on EtOH self-administration when an alternative is concurrently available, male Lewis rats (n = 5) were trained to respond for EtOH and food under a concurrent FR5 FRX schedule where the fixed ratio (FR) for food was adjusted (FR = 25 or 35 for each subject) to provide similar numbers of EtOH and food deliveries during a 30-minute session.

Methods: Doses of varenicline (0.56 to 5.6 mg/kg, i.p.) or vehicle were administered 30 minutes before sessions. Effects of varenicline on responding across the session and during each tenth of the session were compared to responding following vehicle treatment.

Results: Lower doses (0.56 to 1.0 mg/kg) of varenicline increased responding for EtOH without affecting responding for food. Higher doses disrupted responding for EtOH and food similarly.

Conclusions: Previous reports of varenicline selectivity on EtOH-maintained responding do not generalize to other experimental conditions such as a concurrent schedule. The increase in responding for EtOH following lower doses might be due to enhanced EtOH reinforcement, decreased food reinforcement, rate dependency, or greater perseverance on the initial, EtOH response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331054PMC
http://dx.doi.org/10.1111/acer.12085DOI Listing

Publication Analysis

Top Keywords

effects varenicline
12
etoh
12
etoh food
12
responding etoh
12
responding
9
etoh reinforcement
8
etoh alternative
8
varenicline selectivity
8
alternative concurrently
8
056 mg/kg
8

Similar Publications

Introduction: Alcohol use disorder (AUD) is prevalent and recognized as a chronic, relapsing disorder. Even though effective treatment options are available, AUD is strongly undertreated. As adjuvant treatment strategies accompanying psychosocial treatments, pharmacological strategies can increase the efficacy of AUD treatment options.

View Article and Find Full Text PDF

Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial.

Am J Psychiatry

December 2024

Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Blalock); Department of Pediatrics, University of Texas Medical School at Houston (Green); Pfizer Inc., New York (Lawrence); Department of Psychiatry, University of California, San Diego, La Jolla (Anthenelli); Department of Psychiatry, University of Colorado, Aurora (Morris).

Objective: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD).

Methods: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling.

View Article and Find Full Text PDF

Introduction: Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration (FDA)-approved smoking cessation pharmacotherapy [i.e., varenicline, bupropion, nicotine replacement therapy (NRT)].

View Article and Find Full Text PDF

Background: Systematic reviews have documented the beneficial effects of bupropion, cytisine, nicotine, and varenicline as aids to permanent smoking cessation. We investigated the question whether the effect of treatment depends on the severity of tobacco dependence.

Methods: We systematically searched for relevant publications in bibliographic databases and trial registries, made inquiries to manufacturers, and consulted additional sources of information (last search on 1 September 2022).

View Article and Find Full Text PDF
Article Synopsis
  • * Various smoking cessation methods exist, including nicotine replacement therapies and medications like varenicline and bupropion, with new options like cytisine and faster-acting NRTs being developed, enhancing choices for those trying to quit.
  • * Personalizing cessation strategies by assessing individual responses and preferences can lead to more effective treatment outcomes, including the potential use of combination therapies for those who need additional support.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!